As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing adoption in advanced treatment lines, CARVYKTI is poised for substantial revenue growth. LAS...
Read More Details
Finally We wish PressBee provided you with enough information of ( CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma .. DelveInsight )
Also on site :
- Oil prices up after reports of 3 ships on fire in Gulf of Oman near the strait of Hormuz
- Ron Taylor Passes Away
- Barbra Streisand, 83, Makes Spicy Confession About This Hollywood Icon